Skip to main content

Advertisement

Table 3 Construct validity of the Localized Scleroderma Cutaneous Assessment Tool components with global assessment of disease tools

From: Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study

  PhysGA-A PtGA-S
rs (95% CI) p rs (95% CI) p
mLoSSI 0.64 (0.39, 0.79) < 0.01 0.46 (0.16, 0.68) < 0.01
New lesion / lesion extension (N/E) 0.68 (0.45, 0.81) < 0.01 0.3 (−0.02, 0.56) 0.06
Erythema (ER) 0.53 (0.25, 0.72) < 0.01 0.42 (0.11, 0.65) < 0.01
Skin thickness (ST) 0.47 (0.18, 0.69) < 0.01 0.39 (0.07, 0.62) < 0.01
  PhysGA-D PtGA-D
rs (95% CI) p rs (95% CI) p
LoSDI 0.47 (0.17, 0.68) < 0.01 0.24 (−0.09, 0.51) 0.14
Dermal atrophy (DAT) 0.33 (0.01, 0.58) 0.04 0.29 (−0.03, 0.55) 0.07
Subcutaneous atrophy (SAT) 0.44 (0.14, 0.66) < 0.01 0.18 (−0.15, 0.47) 0.27
Dyspigmentation (DP) 0.42 (0.10, 0.64) < 0.01 0.1 (−0.22, 0.40) 0.54
  1. CI confidence interval, mLoSSI modified Localized Scleroderma Skin Severity Index, PhysGA-A physician global assessment of disease activity, PtGA-S patient global assessment of disease severity, LoSDI Localized Scleroderma Damage Index, PhysGA-D physician global assessment of disease damage, PtGA-D patient global assessment of disease damage, rs Spearman’s rank correlation coefficient, p p-value